BEAM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Beam Therapeutics Inc (BEAM) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has strong positive catalysts, including significant revenue growth, a robust pipeline, and positive developments in its therapeutic programs. Despite recent price declines, the long-term outlook is favorable, supported by bullish analyst ratings and strong financial resources.
The technical indicators show mixed signals. The MACD is positive and contracting, indicating potential upward momentum. The RSI is neutral at 51.749, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at $26.197, and resistance is at $32.698. The stock is currently trading below the pivot level of $29.447, suggesting a potential rebound opportunity.
Revenue increased by 279.52% YoY in Q4
The company announced a $500M credit facility to support future growth.
Positive developments in its pipeline, including BEAM-304 for phenylketonuria and risto-cel for sickle cell disease.
Analyst upgrades with increased price targets and positive sentiment.
Hedge funds are significantly increasing their positions.
Insiders are selling, with a 980.39% increase in selling activity over the last month.
Net income and EPS have significantly declined YoY.
The stock has experienced a recent price decline, with a -2.33% regular market change and additional losses in post-market trading.
Beam Therapeutics reported Q4 2025 revenue of $114.11 million, up 279.52% YoY, and a GAAP EPS of $2.33. However, net income dropped by -370.38% YoY, and EPS declined by -317.43%. The company has a strong gross margin of 100% and expects its financial resources to cover operating expenses through mid-2029.
Analysts are bullish on Beam Therapeutics. Recent upgrades include Wedbush raising the price target to $65, Canaccord to $75, and BofA to $47. Analysts highlight the company's robust pipeline, strategic financing agreements, and potential for long-term growth. The consensus view is positive, with several firms maintaining Buy or Outperform ratings.
